WAKE UP AND TREAT DELIRIUM : PITFALLS OF THE PAD GUIDELINES
|
|
- Poppy Black
- 6 years ago
- Views:
Transcription
1 WAKE UP AND TREAT DELIRIUM : PITFALLS OF THE PAD GUIDELINES Tudy Hodgman, Pharm D, FCCM, BCPS The goal of this discussion will be to review the literature published since the PAD guidelines were released and formulate an approach to individualized patient treatment for pain, agitation and delirium in the adult patient in the intensive care unit. I have no financial disclosures to make regarding the contents of this presentation OBJECTIVES Describe Early Goal Directed Sedation. Compare analgosedation to standard sedation approaches. Explain the approach to prevention and treatment of delirium. Review atypical antipyschotics and list common adverse reactions to these agents seen while treating delirium. Identify bedside issues with implementation of an effective program for PAD. Early Goal Directed Sedation (EGDS) o Early implementation after intubation o Goal directed to target LIGHT sedation (RASS -2 to 1) o Use of dexmedetomidine as the primary sedative o Minimizes use of benzodiazpepines Early Goal Directed Sedation (EGDS) Analgosedation Advantages o vent. weaning time o Vent. Time o ICU LOS ouse less hypnotics oless sedation o(? Less ADRx) Disadvantages opotential delirium orecall (unpleasant events) onightmares / hallucinations o? Immunosuppression owithdrawal o Hyperalgesia o Majority of trials used remifentanil Devabhakthuni S et al Ann Pharmacother 2012
2 PAIN Subjective Critically ill patients may be unable to self- report pain The ability to reliably assess pain is foundational for effective treatment Self reporting is GOLD standard PAIN ASSESSMENT If unable to self-report - Use a validated and reliable pain scale Behavioral Pain Scale (BPS) Critical Care Patient Observation Tool (CPOT) Facial expressions Body movements Muscle tension Compliance with ventilator Routinely monitor Identify and treat early rather than waiting until it becomes severe ( OR prior to procedures) Assess ALL PATIENTS for any TYPE of pain OPIOID OPIOID ADVERSE EFFECTS AGENT ONSET COMPARISON & DURATION USUAL DOSE COMMENT CNS effects (confusion, delirium) Sedation (often desirable) Mood changes Respiratory depression May increase time on ventilator Decreased GI motility Bowel regimens for constipation may be necessary Nausea, vomiting & constipation Abrupt discontinuation after prolonged use withdrawal Tolerance / Dependence Fentanyl Morphine Hydromorphone : 1-2 min Duration: 1-4 hr : 5-10 min Duration: 3-5 hr : 5-10 min Duration: 3-5 hr Bolus: mcg IVP q hr Infusion: mcg/kg/hr Bolus: 2-4 mg IVP q 1-2 hr Infusion: mg/hr Bolus: mg IVP q 1-2 hr Infusion: mg/hr Agent of choice Rapid onset/offset Not an issue with renal failure Less hypotension Accumulate w morbid obesity Hypotension 2 histamine release Metabolite accumulation with renal failure Slower onset Not an issue with renal failure Use with intolerance to fentanyl or morphine Meperidine AVOID AVOID with long t ½ which can cause seizures Remifentanil : min Duration: 5 min Bolus: 1 mcg/kg IVP Infusion: mcg/kg/min Renal elimination Interacts with SSRI/ MAO Rapid onset / offset Metabolism by plasma esterases Chest wall rigidity $$$ Opioid ORAL options Equianalgesic Dose Codeine 120 mg 200 mg mg every 4-6 h Oxycodone (OxyContin) Hydrocodone / APAP (Norco, Lorcet, Vicodin) N/A 20 mg 5-15 mg every 4-6 h (IR) N/A 30 mg mg hydrocodone every 4-6 h Methadone N/A N/A mg every 6-12 h Dosing Half-life Metabolism Adverse Effects h Demethylation Glucuronidation h CYP 2D6, 3A h CYP 2D6, 3A h N-demethylation CYP 3A4/5, 2D6, 2B6, 1A2 Histamine release Monitor all sources of acetaminophen Prolonged QTc Unpredictable PK/PD NON OPIOID ANALGESICS Use non-opioid opioid analgesics to: Amount of opioids or eliminate need for IV opioids Opioid related side effects Acetaminophen (Tylenol,, Ofirmev ) Analgesic and antipyretic effects Adverse Effects Hepatotoxicity Rash Neutropenia, leukopenia, pancytopenia NSAIDs Ibuprofen (Motrin) Ketorolac (Toradol)
3 Non-opioid opioid analgesia NSAIDs Drug, route Dosing Time to Ketorolac (Toradol) PO, IM, IV mg q 6 hr (MAX 5 days) > 50 kg: MAX 120mg/d IV/IM, 40mg/d PO Half-life Metabolism 10 min 2-6 hr Hydroxylation Conjugation Renal excretion Neuropathic pain Drug, route Dosing Time to Gabapentin (Neurontin) PO Carbamazepine (Tegretol) PO Initial: 100mg TID mg TID *renally dosed (MAX 3600mg/day) Initial: 100mg BID q 4 6 hr (MAX 1200mg/day) 2 4 hr 5 7 hr Half-life Prolonged in renal insufficiency 4 5 hr hr but variable bc of autoinduction (complete in 3 5 weeks), then h Metabolism Not metabolized CYP3A4 to active epoxide Induces hepatic enzymes < 50 kg &/or CrCL < 30ml/min: 60 mg/d IV/IM, 40 mg/d PO Drug, route Gabapentin (Neurontin) Side Effects and Considerations Sedation, sedation, confusion, dizziness, ataxia Ibuprofen (Motrin) PO, IV 400 mg PO q 4 hr (MAX 2.4 g/day) mg IV q 6 hr over >30 min (MAX 3.2 g/day) PO 25 min PO hr IV hr Oxidation Carbamazepine (Tegretol) Adjust dosing in renal dysfunction Abrupt discontinuation associated with drug withdrawal syndrome, seizures Nystagmus, dizziness, diplopia, lightheadedness, lethargy (Rare: aplastic anemia, agranulocytosis, Stevens-Johnson syndrome or epidermal necrolysis with HLA-B1502 gene) Lexi-comp 2013 Multiple drug interactions due to hepatic enzyme induction All these choices, how do you choose? Propofol Dexmedetomidine Midazolam IV, IM, PO Lorazepam IV, IM, PO after IV Loading Dose Half- Life Initial Dosing- Intermittent 2-5 min 3-11 h 2-4 mg q h min 8-15 h 1-2 mg q 2-6h Initial Dosing- Continuous Infusion 2-4 mg/h (bolus before gtt) 1-2 mg/h (bolus before gtt) Titration Adjust by 1-2 mg/h q30min, bolus with each rate increase Adjust by 1 mg/h q30min; give bolus dose with each rate increase Bind the BZD site on the GABA receptor Potentiates GABA actions /Inhibits CNS Sedative / hypnotic Anxiolytic Induce anterograde amnesia Respiratory depression Diazepam (Valium) IV, PR, PO Alprazolam (Xanax) PO Chlordiazepoxide (Librium) PO Clonazepam (Klonopin) PO Half-Life Initial Dosing- Intermittent 2 5 min h mg/kg IV q 0.5-6h 1 2 h h Start at mg PO TID h h 5 25 mg PO 3-4 times daily Considerations Rapid onset Metabolites can prolong duration with repeated doses Accumulation avoid continuous dosing Anxiety and panic disorders Anxiety 1 4 h h 0.5 mg PO TID Seizures Alcohol withdrawal Panic disorder Midazolam Lorazepam Adverse effects BP Quick onset, short duration is lessened by hepatic, renal impairment or with interacting drugs or length of use BP High doses toxicity (anion-gap metabolic acidosis, renal insufficiency (propylene glycol) Special Considerations Intermittent dosing preferred prolongs sedation, especially in patients with renal failure CYP 450 w more drug interactions Intermittent dosing preferred No active s Diazepam Pain, phlebitis at injection site, extremely long half life Short duration of effect Infusion requires large volume
4 PRECAUTIONS: BENZO S Hypotension upon initiation Caution if hemodynamically unstable Withdrawal Autonomic instability, altered perception, paresthesias, headaches, tremors, and seizures Taper off benzodiazepines if high doses or > 7 days of use Avoid use of flumazenil (BZD antagonist) for reversal withdrawal Propofol Adverse effects Respiratory depression Hypotension / bradycardia Pancreatitits Hypertriglyceridemia - Lipid-based emulsion kcal/ml - Check triglycerides 72 hours Propofol-related Infusion Syndrome (PRIS) Special Considerations Rapid onset / offset Requires a dedicated IV line Drug incompatibility Change tubing every 12 hours DEXMEDETOMIDINE (PRECEDEX ) Central, selective alpha-2 2 agonist Immediate onset, short duration (6 minutes) Has sedative, anxiolytic & analgesic effects but less amnesia May facilitate decreasing doses of analgesics, other sedatives Hepatic elimination, no dose adjustments for renal dysfunction Dexmedetomidine 15 min Peak 1 h Half- Life Adverse effects Hypotension Bradycardia Tachyphylaxis Initial Dosing Initial Dosing- Continuous Infusion h NA mcg/kg/h *do not bolus Minimal respiratory depression Loss of airway reflexes Titration Adjust by 0.1 mcg/kg/h q15 min Special Considerations Dose range listed in product labeling differs from that in literature - No bolus - Higher doses - > 24h administration $$$$$ MONITORING DEPTH OF SEDATION Richmond Agitation Sedation Scale (RASS) and the Sedation Agitation Scale (SAS) are the most valid and reliable tools assessing sedation More precise dosing Reduced use of sedatives & analgesics Shorter duration of mechanical ventilation Reduced need for vasopressors Reduced incidence of over-sedation AGITATION Agitation and anxiety occur frequently in critically ill patients Anxiety: : absence of a sense of well-being, exaggerated feelings of fear, nervousness, or apprehension Agitation: : combination of anxiety and increased motor activity
5 DELIRIUM TYPES OF DELIRIUM An acute brain dysfunction; a disturbance of consciousness and attention Can be hyperactive, hypoactive, or mixed Cardinal feature is inattention Underrecognized 60 80% prevalence of mechanically ventilated patients icudelirium.org DSM-IV, American Psychiatric Association 2000 Ely, SCCM 2012 Ely, JAMA 2004;291:1753 Pisani, AJRCCM 2009;180:1092 Maldonado. Anesthesiology 2003;99:A465 DELIRIUM OUTCOMES Delirium is strongly associated with mortality in adult patients Delirium is strongly associated with LOS in adults Delirium is moderately associated with development of post ICU cognitive impairment in adults DETECTING & MONITORING DELIRIUM Routine monitoring for delirium in all adult patients Confusion Assessment Method for the ICU (CAM-ICU) and the Intensive Care Delirium Screening Checklist (ICDSC) are the most valid and reliable tools in adults Routine monitoring is feasible in practice DELIRIUM RISK FACTORS Baseline risk factors associated with delirium Pre-existing existing dementia History of hypertension History of alcoholism Admission severity of illness Coma is an independent risk factor but linking a definitive relationship between subtypes of coma and delirium requires more study Opioids and delirium Conflicting evidence DELIRIUM RISK FACTORS may be a risk factor for delirium in adults Propofol and delirium insufficient data Vented patients are at risk for delirium, use of dexmedetomidine may be associated with lower incidence compared to benzodiazepines
6 Prevention is the BEST treatment for delirium Treatment options Non-pharmacologic Pharmacologic Antipsychotics Atypical antipsychotics DELIRIUM PREVENTION Early mobilization should be performed whenever feasible to delirium incidence No recommendation for use of pharmacologic agents to prevent delirium No recommendation for combined non- pharmacologic and pharmacologic agents to prevent delirium Neither haloperidol or antipsychotics prevent delirium No recommendation for prophylactic use of dexmedetomidine to prevent delirium DELIRIUM TREATMENT Little data that treatment with haloperidol reduces delirium Atypical antipsychotics may reduce the duration of delirium Do not use antipsychotics in patients at risk for torsades de pointes (history of long QT, patients with meds which QT or patients with prior torsades de pointes) Dexmedetomidine instead of benzodiazepines be used for patients with delirium to reduce its duration Receptors ANTIPSYCHOTICS PROPERTIES Olanzapine Quetiapine Risperidone Ziprasidone Aripiprazole Haloperidol α1, H1, M1 α1, H1, M1 α1, α2, H2 α1 α1, H1 Bioavailability % Half life (H) Renal adjustment No No Yes No No No Dosage form PO, SL, IM PO PO, IM PO, IM PO, IM PO, IM Daily dose (mg) 10 to to to 6 40 to to to 30 DA Adverse effect Anticholinergic effects Comparative Risk of Adverse Effects of Antipsychotic Medications* Aripiprazole (Abilify) Clozapine (Clozaril) Olanzapine (Zyprexa) Quetiapine (Seroquel) Risperidone (Risperdal) Dyslipidemia EPS Hyperprolactinemia Neuroleptic malignant syndrome Postural hypotension Prolonged QT interval Sedation Ziprasidone (Geodon) Protocols and the use of assessment tools Protocol design PAD protocol, algorithms and guidelines Implementation of protocols Use of assessment tools CONSISTENTLY Documentation of assessment Consistency from days to nights Seizures Sexual dysfunction Type 2 DM Weight gain NOTE: 0 = rare; + = lower risk; ++ = medium risk; +++ = higher risk. FGAs = first-generation antipsychotics; SGAs = second-generation antipsychotics; EPS= extrapyramidal symptoms * Effects are approximate, and relative to other antipsychotic medications rather than absolute risk of an adverse effect occurring. MUENCH, J. HAMER, AM. Am Fam Physician Mar 1;81(5):
7 GUIDELINE MANAGEMENT & IMPLEMENTATION Daily interruption or light target level of sedation be used Analgesia be implemented as first sedative Sleep should be promoted to protect the normal sleep cycle GUIDELINE MANAGEMENT & IMPLEMENTATION Multidisciplinary team plus: Provider education Preprinted +/or computerized protocols and order forms ICU rounds checklist be used to assess pain, agitation and delirium ROUTINELY TAKE HOME POINTS QUESTIONS?? Treat pain first Evaluate the pharmacology of agents to select optimal therapy to avoid delirium when possible Sedation: lighter is better than deeper Promote sleep Identify your goal and routinely reassess therapy Use a multi-disciplinary approach
Jennifer Mando-Vandrick, PharmD, BCPS Clinical Pharmacist, Emergency Department Director, PGY2 Critical Care Pharmacy Residency Duke University
Jennifer Mando-Vandrick, PharmD, BCPS Clinical Pharmacist, Emergency Department Director, PGY2 Critical Care Pharmacy Residency Duke University Hospital Objectives Review pertinent pharmacotherapy common
More informationPOST-INTUBATION ANALGESIA AND SEDATION. August 2012 J Pelletier
POST-INTUBATION ANALGESIA AND SEDATION August 2012 J Pelletier Intubated patients experience pain and anxiety Mechanical ventilation, endotracheal tube Blood draws, positioning, suctioning Surgical procedures,
More informationPRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist
PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines
More informationFighting the Fog A Collaborative Approach to Decreasing ICU Delirium
Fighting the Fog A Collaborative Approach to Decreasing ICU Delirium Kimberly Scherr NP Jennifer Barker RN Misericordia Hospital ICU Edmonton, AB CACCN Dynamics Sept 21, 2014 Delirium Delirium is an acute
More informationSEDATION, AGITATION, DELIRIUM Daniel Lollar, MD
SEDATION, AGITATION, DELIRIUM Daniel Lollar, MD OVERVIEW Correctable causes of agitation Pain assessment opioids Agitation assessment BZNs, propofol, precedex comparisons Delirium haldol, antipsychotics
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Pretest 1. Appropriate target symptoms for emergency room medication treatment
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Pretest 1. Which of the following conditions is LEAST likely to benefit from emergency
More informationSedation and delirium- drugs and clinical management
Sedation and delirium- drugs and clinical management Shannon S. Carson, MD Associate Professor and Chief Division of Pulmonary and Critical Care Medicine University of North Carolina Probability of transitioning
More informationGoals for sedation during mechanical ventilation
New Uses of Old Medications Gina Riggi, PharmD, BCCCP, BCPS Clinical Pharmacist Trauma ICU Jackson Memorial Hospital Disclosure I do not have anything to disclose Objectives Describe the use of ketamine
More informationSummary of Delirium Clinical Practice Guideline Recommendations Post Operative
Summary of Delirium Clinical Practice Guideline Recommendations Post Operative Intensive Care Unit Clinical Practice Guideline for Postoperative Clinical Practice Guidelines for the Delirium in Older Adults;
More informationANALGESIA AND SEDATION IN MECHANICAL VENTILATION
ANALGESIA AND SEDATION IN MECHANICAL VENTILATION Erik Stoltenberg, MD Abbott Northwestern Hospital February 27, 2018 DISCLOSURE Nothing to disclose AllinaHealthSystem 1 OBJECTIVE To apply knowledge of
More informationKendiss Olafson MD FRCPC MPH Section of Critical Care University of Manitoba
Kendiss Olafson MD FRCPC MPH Section of Critical Care University of Manitoba Outline Sedation in ICU Purpose/Goals Common Drugs Sedation delivery strategies Mobility in the ICU Weakness with critical illness
More informationInteraction between Sedation and Weaning: How to Balance Them? Guillermo Castorena MD Fundacion Clinica Medica Sur Mexico
Interaction between Sedation and Weaning: How to Balance Them? Guillermo Castorena MD Fundacion Clinica Medica Sur Mexico Balance is not that easy! Weaning Weaning is the liberation of a patient from
More informationDELIRIUM IN ICU: Prevention and Management. Milind Baldi
DELIRIUM IN ICU: Prevention and Management Milind Baldi Contents Introduction Risk factors Assessment Prevention Management Introduction Delirium is a syndrome characterized by acute cerebral dysfunction
More informationPHYSICIAN'S ORDERS Mark in for desired orders. If is blank, order is inactive. VENTILATOR SEDATION / ANALGESIC / DELIRIUM ORDER
Nursing Daily awakenings PHYSICIAN'S ORDERS Mark in for desired orders. If is blank, order is inactive. VENTILATOR SEDATION / ANALGESIC / DELIRIUM ORDER Do not perform daily awakenings: Rationale: Daily
More informationSedative-Hypnotics. Sedative Agents (General Considerations)
Sedative Agents (General Considerations) No best sedative agent Any agent given in sufficient dosage can produce any level of sedation Intravenous dosing is more predictable then intramuscular or oral
More informationThe Difficult to Sedate ICU Patient
The Difficult to Sedate ICU Patient Dan Burkhardt, M.D. Associate Professor Department of Anesthesia and Perioperative Care University of California San Francisco burkhard@anesthesia.ucsf.edu Richmond
More informationCOMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150
More informationImproving the Management of Pain, Agitation, and Delirium (PAD) in the Intensive Care Unit: Translating Evidence Into Practice
Improving the Management of Pain, Agitation, and Delirium (PAD) in the Intensive Care Unit: Translating Evidence Into Practice Christine M. Groth, Pharm.D., BCCCP NYS Partnership for Patients September
More informationComplicated Withdrawal
Complicated Withdrawal Shamim Nejad, MD Director, Adult Burns & Trauma Psychiatry Division of Psychiatry and Medicine Medical Director, Addiction Consultation Team MGH Center for Addiction Medicine Massachusetts
More informationAnalgesia, Sedation and Delirium The Latest Evidence in Assessment & Treatment
Analgesia, Sedation and Delirium The Latest Evidence in Assessment & Treatment Julie Miller, RN, BSN, CCRN How many of you routinely assess for delirium in your patients? 2013 SCCM Guidelines Pain Recommend
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationLumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.
Reference Guide for PACU Lumbar Fusion CLINICAL PATHWAY All patient variances to the pathway are to be circled and addressed in the progress notes. This Clinical Pathway is intended to assist in clinical
More informationUpdate on the Management and Monitoring of Deep Analgesia and Sedation in the Intensive Care Unit
AACN Advanced Critical Care Volume 24, Number 2, pp.101 107 2013, AACN ECG Challenges Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Update on the Management and Monitoring
More informationNorth Wales Critical Care Network
North Wales Critical Care Network SEDATION GUIDELINES FOR ADULTS IN CRITICAL CARE Approved 6.9.12 1 Sedation guidelines for intensive care Betsi Cadwaladr University Health Board (Adapted from guidelines
More informationManaging Delirium: The best way to achieve clarity (of mind) Tim Walsh. Professor of Critical Care, Edinburgh University
Managing Delirium: The best way to achieve clarity (of mind) Tim Walsh Professor of Critical Care, Edinburgh University Lecture Plan: a route to clarity What is delirium? Why is delirium important? Step
More informationComplicated Withdrawal
Complicated Withdrawal Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@Swedish.org Disclosures: Shamim Nejad,
More informationCan Goal Directed Sedation Improve Outcomes?
Can Goal Directed Sedation Improve Outcomes? Yahya SHEHABI, FANZCA, FCICM, EMBA Professor and Program Director Critical care Monash Health and Monash University - Melbourne School of Medicine, University
More informationManagement of Delirium in Hospice Patients
Presentation Objectives Management of Delirium in Hospice Patients Lynn Williams, BSPharm Clinical Pharmacist Hospice Pharmacy Solutions Identify the clinical features of delirium Understand the underlying
More information1
Disclosures I do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies for this continuing education activity, or any affiliation with
More informationICU Liberation for the Pharmacist. A. Kendall Gross, PharmD, BCPS, BCCCP Critical Care Pharmacist UCSF Medical Center
ICU Liberation for the Pharmacist A. Kendall Gross, PharmD, BCPS, BCCCP Critical Care Pharmacist UCSF Medical Center Disclosure No conflicts of interest to disclose Objectives o Outline the elements of
More informationSedation and Delirium Questions
Sedation and Delirium Questions TLC Curriculum William J. Ehlenbach, MD MSc Assistant Professor of Medicine Pulmonary & Critical Care Medicine Question 1 Deep sedation in ventilated critically patients
More informationICU Delirium in Infants & Children: Cause for Concern or False Alarm. Objectives
ICU Delirium in Infants & Children: Cause for Concern or False Alarm Peter (Pete) N. Johnson, Pharm.D., BCPS, BCPPS, FPPAG Associate Professor of Pharmacy Practice University of Oklahoma College of Pharmacy
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationAgonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone
Opioid Definition All drugs, natural or synthetic, that bind to opiate receptors Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone Opioid agonists increase pain threshold
More information+ Change in baseline mental status, inattention, and either disorganized thinking or altered level of consciousness. Delirium. Disclosure.
47 th Annual Meeting August 2-4, 2013 Orlando, FL Identification, Prevention and Treatment of Delirium: The Role of the Health System Pharmacist Jennifer Cortes, PharmD, BCPS Medical ICU Clinical Pharmacy
More informationBenzodiazepines: Comparative Effectiveness and Strategies for Discontinuation. Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project
Benzodiazepines: Comparative Effectiveness and Strategies for Discontinuation Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project This project is funded through a grant from the Pew Charitable
More informationDelirium. Dr. Lesley Wiesenfeld. Deputy Psychiatrist in Chief, Mount Sinai Hospital. Dr. Carole Cohen
Delirium Dr. Lesley Wiesenfeld Deputy Psychiatrist in Chief, Mount Sinai Hospital Dr. Carole Cohen Department of Psychiatry, University of Toronto and Sunnybrook Health Sciences Centre Case Study Mrs B
More informationAnxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Anxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the normal processing of fear vs fear processing
More informationDelirium. Assessment and Management
Delirium Assessment and Management Goals and Objectives Participants will: 1. be able to recognize and diagnose the syndrome of delirium. 2. understand the causes of delirium. 3. become knowledgeable about
More informationOverview of Presentation. Delirium Definition. Assessing & Managing ICU Delirium: What is the Evidence?
Assessing & Managing ICU Delirium: What is the Evidence? Dale Needham, MD, PhD Professor Pulmonary & Critical Care Medicine, and Physical Medicine & Rehabilitation Medical Director, Critical Care Physical
More informationAppendix A: Pharmacologic approaches to pain management during MVA
Pain medication Though the medications shown below are commonly used for pain management during uterine evacuation, many other options exist. This table does not cover general anesthetic agents. Both anxiolytics
More informationSedation of the Critically Ill Patient
Buffalo theory of sedation It s a well known fact that a herd of buffalo can only move as fast as the slowest buffalo. And when the herd is hunted, it s the slowest and weakest ones at the back that are
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationAcute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX
Acute Pain Management in the Hospital Setting Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX 2 What is Pain? An unpleasant sensory and emotional experience associated
More informationExtreme arousal, irritability, excess motor activity driven by internal sense of discomfort such as disease, pain, anxiety and delirium
Agitated patient in ICUapproach & management Arjun Srinivasan Agitation Extreme arousal, irritability, excess motor activity driven by internal sense of discomfort such as disease, pain, anxiety and delirium
More informationPain, Agitation & Delirium (2013) Immobility & Sleep (2018) Catherine Jones Practice Educator GICU October 2018
Pain, Agitation & Delirium (2013) Immobility & Sleep (2018) Catherine Jones Practice Educator GICU October 2018 1 Plan for session Why Pain Agitation & Delirium are important considerations in critical
More informationOptimal sedation and management of anxiety in patients undergoing endobronchial ultrasound (EBUS)
Optimal sedation and management of anxiety in patients undergoing endobronchial ultrasound (EBUS) Georgios Dadoudis Anesthesiologist ICU DIRECTOR INTERBALKAN MEDICAL CENTER Optimal performance requires:
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationAnalgesic-Sedatives Drug Dose Onset
Table 4. Commonly used medications in procedural sedation and analgesia Analgesic-Sedatives Fentanyl Morphine IV: 1-2 mcg/kg Titrate 1 mcg/kg q3-5 minutes prn IN: 2 mcg/kg Nebulized: 3 mcg/kg IV: 0.05-0.15
More informationANTIANXIETY DRUGS: BENZODIAZEPINES
Margaret Gnegy Professor of Pharmacology pgnegy@umich.edu 1 ANTIANXIETY DRUGS: BENZODIAZEPINES Sedatives and hypnotics M. Gnegy, Ph.D. 1 2 Reading: Goodman & Gilman, 11th ed. Chapter 16, pp. 401-427. Drug
More informationP-RMS: FR/H/PSUR/0036/001
Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,
More informationClinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients
Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit January 2013 Volume 41 Number 1 Society of Critical Care Medicine 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時,
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:
Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated
More informationOPIOID- INDUCED NEUROTOXICITY*
OPIOID- INDUCED NEUROTOXICITY* Sriram Yennu MD, MS, FAAHPM Palliative Care, Rehabilitation and Integrative Medicine U.T. M.D. Anderson Cancer Center *Slide Deck courtesy Dept PRIM MDACC PATIENT #1: MRS
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationApproach to agitated patient in ICU
Approach to agitated patient in ICU 12-2-2016 Kodati Rakesh Senior resident Pulmonary medicine Agitation Psychomotor disturbance characterized by a marked increase in both motor and psychological activities,
More informationDexmedetomidine: the various roles and utilization strategies. Julie Belfer, PharmD September 2014
Dexmedetomidine: the various roles and utilization strategies Julie Belfer, PharmD September 2014 Disclosure No disclosures concerning possible financial or personal relationships with commercial entities
More informationInterprofessional Trauma Conference September 28th 2018 Montreal
Interprofessional Trauma Conference September 28th 2018 Montreal Marc Perreault & Marc Alexandre Duceppe ICU Pharmacists MGH & RVH-CUSM Faculté de Pharmacie Université de Montréal I have no potential conflict
More information4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
More informationComfort Management in the Adult with Congenital Heart Disease What the ICU Bedside Nurse Needs to Know
Comfort Management in the Adult with Congenital Heart Disease What the ICU Bedside Nurse Needs to Know Sandy Staveski RN, MS, CPNP-AC/PC, CNS, CCRN Pediatric Intensive Care Nurse Practitioner Lucile Packard
More informationMay 2013 Anesthetics SLOs Page 1 of 5
May 2013 Anesthetics SLOs Page 1 of 5 1. A client is having a scalp laceration sutured and is to be given Lidocaine that contains Epinephrine. The nurse knows that this combination is desgined to: A. Cause
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationDelirium in the ICU: Prevention and Treatment. Delirium Defined Officially. Delirium: Really Defined. S. Andrew Josephson, MD
Delirium in the ICU: Prevention and Treatment S. Andrew Josephson, MD Director, Neurohospitalist Service Medical Director, Inpatient Neurology June 2, 2011 Delirium Defined Officially (DSM-IV-TR) criteria
More informationDelirium Monograph - Update, Spring 2014
Delirium Monograph - Update, Spring 2014 Since publication of the APM monograph on Delirium in January 2012, three structured reviews have been published adding data relevant to the practice of identification,
More informationAnalgosedation: What Strategy is Best? Guillermo Castorena MD Fundación Clínica Médica Sur México
Analgosedation: What Strategy is Best? Guillermo Castorena MD Fundación Clínica Médica Sur México The facts Despite the efforts to optimize sedation and comfort of ICU s patients: More than 50% of patients
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationComfort Management in the Adult with Congenital Heart Disease What the ICU Bedside Nurse Needs to Know
Comfort Management in the Adult with Congenital Heart Disease What the ICU Bedside Nurse Needs to Know Sandy Staveski RN, PhD, CPNP-AC/PC, CNS; Cincinnati Children s Hospital Medical Center Mary Rummell,
More informationB. Long-acting/Extended-release Opioids
4 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone
More informationSedation For Cardiac Procedures A Review of
Sedation For Cardiac Procedures A Review of Sedative Agents Dr Simon Chan Consultant Anaesthesiologist Department of Anaesthesia and Intensive Care Prince of Wales Hospital Hong Kong 21 February 2009 Aims
More informationAppendix D: Drug Tables
Appendix D: Drug Tables A. Short-acting, Orally Administered Opioids Table D-1: Use of Short-acting, Orally Administered Opioids in Adults [198] Additional Maximum APAP dose: 4000 mg/d (2000 mg/d in chronic
More informationVentilator-Associated Event Prevention: Innovations
Ventilator-Associated Event Prevention: Innovations Michael J. Apostolakos, MD Professor of Medicine Director, Adult Critical Care University of Rochester Mobility/Sedation in the ICU Old teaching: Keep
More informationAnxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationPAIN PODCAST SHOW NOTES:
PAIN PODCAST SHOW NOTES: Dallas Holladay, DO Ultrasound Fellow Cook County Hospital Rush University Medical Center Jonathan D. Alterie, DO PGY-2, Emergency Medicine Midwestern University An overview of
More informationComplicated Withdrawal
Complicated Withdrawal Shamim Nejad, MD Medical Director, Division of Psychosocial Oncology Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@Swedish.org Disclosures: Shamim
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationSTARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION
STARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION Patients receiving analgesia and/or sedation for longer than 5-7 days may suffer withdrawal if these drugs are suddenly stopped. To prevent this happening
More informationLorazepam Tablets, USP
Lorazepam Tablets, USP DESCRIPTION: Lorazepam, an antianxiety agent, has the chemical formula, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H -1,4-benzodiazepin-2-one: Cl H N N O Cl OH It is a white
More informationSymptom Management Challenges at End-of-Life
Symptom Management Challenges at End-of-Life Amanda Lovell, PharmD, BCGP Clinical Pharmacist- Inpatient Units Optum Hospice Pharmacy Services February 15, 2018 Hospice Pharmacy Services Objectives Identify
More informationNon-opioid and adjuvant pain management
Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR
More informationDelirium in Cancer: Psychopharmacologic Management
Delirium in Cancer: Psychopharmacologic Management William Breitbart, MD Professor and Chief, Psychiatry Service Memorial Sloan-Kettering Cancer Center New York, New York Delirium in Patients with Cancer
More informationPain Management Strategies Webinar/Teleconference
Pain Management Strategies Webinar/Teleconference Barry K. Baines, MD April 16, 2009 Objectives Describe the principles of pain management. Identify considerations in the use of opioids. Describe the benefits
More informationManagement of Delirium in the ICU. Yahya Shehabi
Management of Delirium in the ICU Yahya Shehabi Hello! Doctor, your patient is CAM + ve Good morning Dr, Am one of the RC, Just examined Mr XXX he is CAM +ve Positive what? Sir replied RC: I meant he is
More informationCHAMP: Bedside Teaching TREATING PAIN. Stacie Levine MD. What is the approach to treating pain in the aging adult patient?
CHAMP: Bedside Teaching TREATING PAIN Stacie Levine MD Teaching Trigger: An older adult patient is identified as having pain. Clinical Question: What is the approach to treating pain in the aging adult
More informationDelirium. A Plan to Reduce Use of Restraints. David Wensel DO, FAAHPM Medical Director Midland Care
Delirium A Plan to Reduce Use of Restraints David Wensel DO, FAAHPM Medical Director Midland Care Objectives Define delirium Describe pathophysiology of delirium Understand most common etiologies Define
More informationSarah V. Cogle, PharmD, BCCCP Assistant Clinical Professor Auburn University Harrison School of Pharmacy Auburn, AL ALSHP Annual Clinical Meeting
Sarah V. Cogle, PharmD, BCCCP Assistant Clinical Professor Auburn University Harrison School of Pharmacy Auburn, AL ALSHP Annual Clinical Meeting 2018 I have no actual or potential conflict of interest
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationNURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOL USE OF PROPOFOL (DIPRIVAN) FOR VENTILATOR MANAGEMENT
NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOL I. PURPOSE: To provide guidelines for the administration of Propofol, which is an anesthetic agent, indicated for the continuous intravenous
More informationCanadian Practices for the Treatment of Delirium. Lisa Burry, BScPharm, PharmD
Canadian Practices for the Treatment of Delirium Lisa Burry, BScPharm, PharmD Disclosures & Acknowledgements Conflicts of interest: None Acknowledgements: our patients and the clinical staff that supported
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationAnxiolytic & Hypnotic Drugs. Asst Prof Dr Inam S Arif
Anxiolytic & Hypnotic Drugs Asst Prof Dr Inam S Arif isamalhaj@yahoo.com Anxiolytic & Hpnotic Agents Anxiety: unpleasant state of tension, apprehension or uneasiness, characterised by, tachycardia, sweating,
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationPediatric Procedural Sedation
Pediatric Procedural Sedation Case 1: 2 year old complex facial laceration Judith R. Klein, MD, FACEP Assistant Professor of Emergency Medicine UCSF-SFGH Department of Emergency Medicine Objectives: The
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationPharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:
0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:
More informationBenzodiazepines. Benzodiazepines
: History 1950s - Invented by Swiss chemists who identified its sedative effects 1950s 60s - Chlordiazepoxide (Librium) marketed as a safer alternative to barbiturates; along with newer benzodiazepines
More informationSedation Guidelines for Air Ambulance Transfer of Psychiatric Patients
Sedation Guidelines for Air Ambulance Transfer of Psychiatric Patients 1 Determine transfer risks as per BC Ambulance Risk Stratification Tool 2 Determine required sedation level accordingly: RASS Level
More information